SCHEMBL1418995

SCHEMBL1418995

COC(=O)CN(C)C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.65
▸ ERBB2 P04626 9/20 0.63
▸ JAK3 P52333 1/20 0.57
▸ ERBB4 Q15303 1/20 0.57
▸ KDM4E B2RXH2 1/20 0.55
▸ GAK O14976 1/20 0.55
▸ MAPK13 O15264 1/20 0.55
▸ ABL1 P00519 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CDK1 P06493 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ FBP1 P09467 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ SRC P12931 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ EPHB2 P29323 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1418997 1.00 EGFR (0.65) EGFRERBB2JAK3ERBB4KDM4E
SCHEMBL1418061 0.95 EGFR (0.62) EGFRERBB2JAK3ERBB4
SCHEMBL1418063 0.95 EGFR (0.62) EGFRERBB2JAK3ERBB4
SCHEMBL1418182 0.94 EGFR (0.62) EGFRERBB2JAK3ERBB4KDR
SCHEMBL1418183 0.94 EGFR (0.62) EGFRERBB2JAK3ERBB4KDR
SCHEMBL1418259 0.93 EGFR (0.60) EGFRERBB2JAK3ERBB4
SCHEMBL1417866 0.93 EGFR (0.60) EGFRERBB2JAK3ERBB4
SCHEMBL1417867 0.93 EGFR (0.60) EGFRERBB2JAK3ERBB4
SCHEMBL1418260 0.93 EGFR (0.60) EGFRERBB2JAK3ERBB4
SCHEMBL1418886 0.92 EGFR (0.61) EGFRERBB2JAK3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298746-A1 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2011-03-23 — — EP disclosed
US-6972288-B1 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-12-06 — — US disclosed
Send feedback